

Quantitative Imaging Biomarkers Alliance (QIBA):

QIBA announces the completion of two standardized Profile documents relevant for acquiring and analyzing images used in cancer studies and treatments. These QIBA Profiles describe methods for obtaining accurate and reproducible 18F-fluorodeoxyglucose (FDG) PET/CT measurements

[https://www.rsna.org/uploadedFiles/RSNA/Content/Science_and_Education/QIBA/QIBA_FDG-PET_Profile_v105_Publicly_Reviewed_Version_FINAL_11Dec2013.pdf] and CT tumor volume measurements

[https://www.rsna.org/uploadedFiles/RSNA/Content/Science_and_Education/QIBA/QIBA_CT%20Vol_TumorVolumeChangeProfile_v2.2_PubliclyReviewedVersion_08AUG2012.pdf].

Image-based assessments of treatment response can be highly variable, depending on the make and model of the imaging equipment used and how the images were acquired, processed, and interpreted. Standardizing the use of quantitative imaging biomarkers in clinical trials and patient care can reduce the variance inherent across different hardware and software platforms used in different research and treatment centers, making it easier to compare the results of one imaging study with another in the same patient, or between groups of patients in a clinical trial, or between studies or institutions. QIBA engages the efforts of more than 1000 volunteers from academia, industry, and government, with financial support from Radiological Society of North America and National Institute of Biomedical Imaging and Bioengineering and in-kind contributions from the Food and Drug Administration and National Institute of Standards and Technology, to develop standardized approaches to measuring quantitative imaging biomarkers. More than 160 volunteers contributed to the QIBA profiles for FDG PET/CT and CT tumor volume measurement. The ability to measure disease and response to treatment reliably is a critical tool in the cancer fighting arsenal. To improve the reliability of cancer imaging studies, a growing number of medical practices, imaging vendors, research organizations, and other entities are announcing their commitment to endorse or adopt these two QIBA profiles. Each year, some 23 million CT scans and 1.6 million PET scans are performed as part of cancer-related care. Use of these QIBA Profiles for standardized quantitative imaging will contribute significantly to improvements in the quality of cancer care, as well as substantially aiding in the development pathway for more effective therapeutics in oncology.

2. Statements of Support for Quantitative Imaging Biomarkers Alliance (QIBA) Profiles (Industry, December 2016):

We, the undersigned, endorse the motivation, goals and concepts of QIBA Profiles to standardize QIBs in cancer research and cancer care. We agree that use of these standardized quantitative imaging QIBA Profiles will contribute significantly to improvements in the quality and productivity of in the cancer clinic, as well as substantially aiding in the development of novel therapeutics in oncology.

Name, Title	Affiliations (optional)
Annette Schmid, PhD	Translational and Early Clinical- Imaging, Takeda
Gregory Goldmacher, MD, PhD, MBA	
Terri A. Binder, MS, DMD, PhD	
Harris Ahmad, MD	
Xiaozhou Ma, MD	
David E. Gustafson, Ph.D.	
Brian S Garra, M.D.	Washington DC VA Medical Center
Ira Smalberg, MD	
Eliot Siegel, M.D.	University of Maryland School of Medicine/VA Maryland Healthcare System
Rick Patt, MD	RadMD
Rick Jacobs	PAREXEL
Ivalina Hristova	
Anurag Gupta, PhD	
James Conklin MD, MS	Independent Consultant
Alpana Harisinghani	PAREXEL
Dewen Yang, MD, PhD	ICON
Paul Galette	GSK
Theresa Tuthill, PhD	Pfizer
Kevin Maresca, PhD	Pfizer
John Pearson, PhD	American College of Radiology
Dwaine Rieves, MD	Independent Consultant

